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Although venous thromboembolism (VTE) is common in patients with cancer, it is not known if it is associated with risk of a second
malignancy. Using the Danish Cancer Registry and National Registry of Patients, we studied a population-based cohort of 6285
patients with cancer who had an episode of VTE. The risk of a second cancer was compared with that among 30713 cancer patients
without VTE, matched for age, sex, cancer site and year of diagnosis. Overall, the relative risk for a second cancer diagnosis was 1.3
(95% confidence interval (CI) 1.1–1.4). However, the excess risk varied with the time from the initial cancer diagnosis to the
thrombotic event. If the thrombotic episode occurred within the first year, the relative risk for a second cancer was 1.0 (95% CI 0.9–
1.3), but if the VTE occurred more than 1 year after the initial cancer, the overall relative risk for a second cancer was 1.4 (95% CI
1.2–1.7), with strong associations for cancers of the digestive organs, ovary and prostate. The association between VTE and
subsequent incident cancer extends to patients who already have had a cancer diagnosis.
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The association between cancer and venous thrombosis has been
recognised for more than 100 years (Piccioli et al, 1996), since
episodic migratory thrombophlebitis was first reported in patients
with cancer by Trousseau (Sørensen and Baron, 2005). Patients
with clinically overt cancer may develop venous thromboembolism
(VTE) at any stage of the disease (Agnelli, 1997; Rickles and
Levine, 2001), aggravated by surgery, chemotherapy and intra-
venous catheters (Rickles and Levine, 2001). Occasionally, the
thromboembolic event may occur before the clinical presentation
of the cancer, and it is well known that the risk of a first cancer
diagnosis is greatly increased in the year immediately after VTE
(Prandoni et al, 1992; Baron et al, 1998; Sørensen et al, 1998, 2000;
Murchison et al, 2004).
The implications of cancer risk subsequent to venous throm-
bosis for patients with a previous cancer are less clear. An episode
of VTE is a marker of a poor cancer prognosis (Sørensen et al,
2000), but it is not known if this is associated with an increased
risk of a second malignancy, as in patients without prevalent
cancer. Since this may have important clinical implications for the
care of cancer patients, we investigated the risk of a second cancer
in patients with a known malignancy who experienced an episode
of deep venous thrombosis or pulmonary embolism, using
population-based data from the Danish Cancer Registry and
National Registry of Patients.
MATERIALS AND METHODS
This population-based study was based on a cohort of 45201
patients with VTE identified through the Danish National Registry
of Patients. This registry, established in 1977, includes information
on 99.4% of all admissions to Danish acute care nonpsychiatric
hospitals (Andersen et al, 1999). Recorded information includes
the civil registration number (unique to each Danish citizen), the
dates of admission and discharge, the surgical procedures
performed and up to 20 discharge diagnoses, classified according
to the Danish version of the International Classification of
Diseases, 8th edition (ICD-8) (Andersen et al, 1999) until the
end of 1993, and ICD-10 thereafter. It is possible to obtain the full
discharge history of a patient by linking discharge records with the
civil registration number. Study subjects were identified by
searching for patients who had a first time discharge diagnosis
of either lower limb deep venous thrombosis or pulmonary
embolism (ICD-8 codes 451.00 and 450.99; ICD-10 codes I26,
I80.1, I80.2 and I80.3) during at least one hospitalisation between
1 January 1977 and 31 December 1999.
To identify members of the VTE cohort with prevalent cancers
(other than nonmelanoma skin cancer), we used civil registration
numbers to link them to the Danish Cancer Registry (Storm et al,
1997). Here, cancers are classified according to the modified
Danish version of the ICD, 7th Revision. Registration is based on
notification forms completed by hospital departments and
practicing physicians whenever a case of cancer is diagnosed or
found at autopsy and whenever there are changes in an initial
diagnosis. The Registry has been in operation since 1943 and is
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cohort, we identified 10107 patients who had had a cancer
diagnosis prior to the VTE hospitalisation (4711 with deep venous
thrombosis, 5312 with pulmonary embolism and 84 with both
diagnoses): 3822 patients died during the hospital admission for
VTE, leaving 6285 patients for follow-up.
As a control cohort, we selected from the Cancer Registry
patients with a primary cancer diagnosis but without evidence of
VTE in the National Registry of Patients. For each VTE cancer
case, five cancer controls were identified, matched on age (within
5 years), sex, primary cancer site and year of cancer diagnosis.
We required each control to be alive on the discharge date of the
corresponding case for VTE.
Statistical analysis
Members of both study cohorts were linked through their civil
registration numbers to the nationwide Danish Civil Registration
System (with electronic records on vital status, including dates of
emigration and death for the entire Danish population), and to the
Danish Cancer Registry to identify subsequent deaths and cancer
diagnoses. Both cohorts were followed from the date of the case
VTE hospitalisation until the date of a second cancer (other than
nonmelanoma skin cancer), censoring from death or emigration,
or end of follow-up (31 December 1999), whichever came first. We
estimated the relative risk by comparing the incidence of a second
primary cancer between the VTE cancer patients and the cancer
controls, using rate ratios with 95% confidence intervals (CI)
computed from proportional-hazard regression models. We also
computed these rate ratios within two strata of time between the
first primary cancer and the thrombosis hospitalisation (a year or
less, vs more than 1 year). We estimated cumulative risks using
life-table methods.
RESULTS
The mean age of the 6285 members of the VTE cancer cohort was
68.6 years (standard deviation 12.2); 46.1% were men. The cancer
sites most heavily represented in the cohort were breast (13.8%),
colon (10.0%), prostate (9.6%), lymphatic system (9.1%), urinary
tract (7.7%), rectum (6.8%), lung (6.8%) and corpus uteri (5.6%).
In 974 patients (15.5%), the first episode of VTE occurred within a
month of the initial cancer diagnosis.
A total of 343 second cancers were diagnosed in the VTE cancer
cohort compared with 1981 in the control cancer cohort, yielding a
relative risk during the entire follow-up of 1.3 (95% CI 1.1–1.4).
The relative risks were slightly lower for those over 70 years of age,
1.2 (95% CI 1.1–1.4) than for those younger, 1.4 (95% CI 1.2–1.7),
but were almost identical for men and women (data not shown).
For the various second malignancies, relative risks for cancers of
the upper gastrointestinal tract, ovary and prostate were particu-
larly increased (Table 1).
Figure 1 shows the evolution over time of the cumulative risk of
a second cancer in the two cohorts. In the first year after the VTE,
there was a second cancer diagnosis for 2.3% of the VTE cancer
patients and for 1.4% of cancer controls (relative risk 1.6, 95% CI
1.3–2.0) (Table 1).
Of the 3339 VTE cancer cohort members alive 1 year after the
thrombotic event and without a second cancer up to that time, 238
had a diagnosis of a malignancy at a later time (years 2–23 of
follow-up) vs 1610 second cancers among 21713 1-year survivors
in the control cancer cohort (relative risk 1.1, 95% CI 1.0–1.3)
(Table 2). There was little variation over time in the relative risks
during this period (data not shown). Cancer of the prostate and
colorectal cancer were the only cancer sites with significantly
elevated thrombosis-associated risks that persisted beyond the first
year of follow-up.
The risk of a second cancer varied with the interval between the
first cancer and the VTE episode. Patients with a thromboembolic
event more than a year after their cancer diagnosis had a 40%
increase in risk for a second cancer (relative risk 1.4, 95% CI 1.2–
1.7). The relative risk of a second cancer was slightly higher
(relative risk 1.7, 95% CI 1.3–2.2) in the first year after the
thrombotic event, but there was also a clear increase in cancer risk
Table 1 Relative risk (rate ratio) of a second cancer among thrombosis cancer patients and control cancer patients in the first year of follow-up
VTE cancer cohort, N¼6285 Control cancer cohort, N¼30713
Sites of second cancer (ICD-7 code)
a
No. of
events
No./1000
person-year
No. of
events
No./1000
person-year
Relative
risk (95% CI)
All 105 24.3 371 14.5 1.6 (1.3–2.0)
Oesophagus (150) 3 0.7 8 0.3 2.2 (0.6–8.4)
Colon, rectum (153, 154) 13 3.0 55 2.2 1.4 (0.8–2.5)
Liver, primary, gall bladder, pancreas (155.0, 155.1, 157) 13 3.0 23 0.9 3.2 (1.6–6.4)
Lung, primary (162) 16 3.7 67 2.6 1.4 (0.8–2.4)
Breast (170) 7 2.2 181 1.8 1.3 (0.9–1.9)
Ovary (175) 5 1.2 6 0.2 5.0 (1.5–16.3)
Prostate (177) 11 2.5 29 1.1 2.2 (1.1–4.3)
Kidney, bladder (180, 181) 13 3.0 48 1.9 1.6 (0.9–2.9)
Lymphatic and haematological (200–205) 5 1.2 20 0.8 1.5 (0.6–4.0)
VTE¼venous thromboembolism; CI¼confidence interval.
aModified version of the 7th International Classification of Diseases.
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Figure 1 Cumulative risk of a second cancer among cancer cases with
venous thromboembolism and cancer controls.
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1.6) (Table 3). In contrast, cancer patients hospitalised with VTE
within 1 year of the first cancer diagnosis had exactly the same
overall risk of a subsequent second cancer as controls (relative risk
1.0, 95% CI 0.9–1.3). These patients with early thrombosis did
have an increased cancer risk in the first year after the VTE
(relative risk 1.6; 95% CI 1.1–2.3), but this was followed by a
subsequent period of slightly lower cancer risk, which brought the
overall relative risk to unity (Table 3).
Table 4 shows the cumulative 1-year risks of a second primary
cancer in subgroups of patients with VTE more than 1 year
after the first cancer. Particularly, high risks of a second cancer
were seen for patients with kidney and bladder cancer (1 year
cumulative risk 4.5%, 95% CI 2.3–6.7).
DISCUSSION
In this large nationwide follow-up study of cancer patients, we
found an increased risk of second cancers associated with VTE,
largely among patients whose thrombotic episode occurred 1 or
more years after the first primary cancer. Risks of cancers of the
ovary, prostate, hepatobiliary tract and pancreas were increased in
the first year after the thrombosis diagnosis; there was a longer-
term substantial increase in risk only for prostate and colorectal
cancer.
The associations we observed with second cancers parallels that
for a first malignancy, in which risk is also increased soon after a
thrombotic episode (Baron et al, 1998; Sørensen et al, 1998;
Prandoni, 2002). The spectrum of thrombosis-associated second
cancers is very similar to that for first cancers (Baron et al, 1998;
Sørensen et al, 1998), and thus similar aetiologic factors may be at
play.
Among patients with early VTE – within a year of the first
cancer diagnosis – increased surveillance is likely to be a factor in
explaining the pattern of increased risks followed by decreased
risks. The absence of such a pattern for patients with a later
thrombotic episode suggests that diagnostic bias is probably not
a factor, and implies that the association in this group has a
biological basis. The variation over time in the relative risks
provides some clues regarding this issue.
It is implausible that VTE or its treatment could cause a second
solid tumour to develop within a year or two. Indeed, if the
thrombotic event somehow contributed to the aetiology of the
second cancer, we would have expected the relative risks to
increase with follow-up, reflecting the long latency period of most
epithelial cancers (Baron et al, 1998). If, on the other hand, shared
risk factors were underlying the association, a more or less
constant excess risk over time would be expected, as seen among
patients with a thrombotic episode more than 1 year after the
first cancer diagnosis. These risk factors could theoretically be
smoking, obesity and hormone replacement therapy, since these
factors are suggested or established risk factors for both VTE and
cancer (Baron et al, 1998). However, the cancers with the increased
relative risks in association with venous thrombosis – ovary,
Table 2 Relative risk (rate ratio) of a second cancer of selected sites among thrombosis cancer patients and control cancer patients during 2–23 years of
follow-up
VTE cancer cohort, N¼3339 Control cancer cohort, N¼21713
Sites of second cancer (ICD-7 code)
a
No. of
events
No./1000
person-year
No. of
events
No./1000
person-year
Relative
risk (95% CI)
All 238 18.2 1610 15.8 1.1 (1.0–1.3)
Oesophagus (150) 4 0.3 22 0.2 1.4 (0.5–4.0)
Colon, rectum (153, 154) 47 3.6 254 2.5 1.4 (1.1–2.0)
Liver, primary, gall bladder, pancreas (155.0, 155.1, 157) 11 0.8 89 0.9 0.9 (0.5–1.8)
Lung, primary (162) 30 2.3 276 2.7 0.8 (0.6–1.2)
Breast (170) 29 2.2 181 1.8 1.3 (0.9–1.9)
Ovary (175) 3 0.2 33 0.3 0.7 (0.2–2.3)
Prostate (177) 30 2.3 121 1.2 1.8 (1.2–2.7)
Kidney, bladder (180, 181) 22 1.7 194 1.9 0.9 (0.6–1.3)
Lymphatic and haematological (200–205) 18 1.4 129 1.3 1.1 (0.7–1.8)
VTE¼venous thromboembolism; CI¼confidence interval.
aModified version of the 7th International Classification of Diseases.
Table 3 Relative risk (rate ratio) of a second cancer diagnosis (n¼343)
among cancer patients (n¼6285) with venous thromboembolism by time
after first cancer diagnosis
Follow-up interval
Interval
between
first cancer
and VTE
Number of
VTE cancer
patients/controls
First
year 1+ years Overall
Overall 6285/30713 1.6 (1.3–2.0) 1.1 (1.0–1.3) 1.3 (1.1–1.4)
0–1 year 3081/14896 1.6 (1.1–2.3) 0.9 (0.7–1.1) 1.0 (0.9–1.3)
41 year 3204/15817 1.7 (1.3–2.2) 1.4 (1.2–1.6) 1.4 (1.2–1.7)
VTE¼venous thromboembolism.
Table 4 Cumulative 1-year risk of a second cancer in patients with an
episode of VTE more than 1 year after the first cancer
Variable
Number of
subjects
at risk
Cumulative
absolute risk
a
All 3204 2.7 (2.1–3.3)
Women 1764 2.6 (1.7–3.4)
Men 1440 2.9 (1.9–3.8)
o 70 years 1386 2.9 (1.9–3.9)
X70 years 1818 2.7 (1.8–3.5)
Site of first cancer (ICD-7 code)
Colon, rectum (153, 154) 489 2.9 (1.9–3.9)
Breast (170) 607 1.2 (0.2–2.2)
Prostate (177) 352 2.7 (0.7–4.7)
Kidney, bladder (180, 181) 423 4.5 (2.3–6.7)
Lymphatic and haematological (200–205) 261 2.4 (0.3–4.5)
Other 1072 3.3 (2.0–4.5)
VTE¼venous thromboembolism; ICD-7¼7th International Classification of Dis-
eases.
aPercentage.
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these lifestyle risk factors. On balance, it is most likely that the
second cancer was occult and caused the venous thrombosis,
conceivably through changes in the clotting pathway (Silverstein
and Nachman, 1992; Zacharski et al, 1992).
Our study has both strengths and limitations. The large
population we studied was well defined and the long-term
follow-up complete, because our design relied on computerised
registries with complete nationwide coverage. This prevented
selection bias and gave us a relatively high statistical precision. It is
also well known that many cancers are associated with an
increased risk of a second malignancy (Curtis et al, 1994;
Leone et al, 1999; Levi et al, 1999; Brenner et al, 2000), and
we therefore used other patients with incident cancers as
controls. Our use of routine data underlies another strength: since
the study itself did not affect the diagnostic process, it could not
introduce surveillance bias in follow-up. On the other hand, we
identified cases of VTE through an administrative database, the
Danish National Registry of Patients, which may not be entirely
accurate. This misclassification has been estimated to approxi-
mately 8–20% in Sweden and the US (Kniffin et al, 1994;
Schulman and Lindmarker, 2000). Any misclassification of VTE
in the hospital discharge records would cause bias towards the null
hypothesis. As noted above, differential surveillance might also
play a role.
The absolute risk of a second cancer after thromboembolism is
relatively low (about 2% over the first year), and so the benefit of
screening for a second cancer in cancer/thrombosis patients seems
limited. Detection of a second malignancy would require an
extensive work-up with high costs to detect a relatively small
number of cancers. Moreover, the sites of the second malignancies
are not those for which effective screening programmes have been
devised and it is unclear if screening for a second cancer in this
setting would change prognosis.
Over the past 20 years, there has been increasing clinical
evidence that anticoagulants have antitumour effects reducing the
risk of cancer in patients with VTE and improving survival in
patients with advanced malignancy (Zacharski et al, 1981;
Schulman and Lindmarker, 2000; Kakkar et al, 2004). Cancer
patients with VTE are at increased risk of second malignancies, but
further work is needed before specific guidelines for their
management would be appropriate.
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